| ![]() |
||
MRDAC: CT 4003 - An open-label, uncontrolled, Phase II trial evaluating the single-dose and steady-state pharmacokinetics of EndoTAG(R)-1 and its effect on the blood supply and the angiogenesis of hepatic metastases in patients with a carcinomatous primary tumor other than hepatocellular (HCC), biliary or bile duct carcinoma (in collaboration with MediGene AG, Martinsried)Projektbeschreibung:CT 4003 - An open-label, uncontrolled, Phase II trial evaluating the single-dose and steady-state pharmacokinetics of EndoTAG(R)-1 and its effect on the blood supply and the angiogenesis of hepatic metastases in patients with a carcinomatous primary tumor other than hepatocellular (HCC), biliary or bile duct carcinoma.Projektlaufzeit: Projektbeginn: 01.11.2007Projektleitung: Hennig J.Finanzierung:
Schlagworte:
Aktueller Forschungsbericht |